Objective: To characterize in vivo signatures of pathological diagnosis in a large cohort of patients with primary progressive aphasia (PPA) variants defined by current diagnostic classification. Methods: Extensive clinical, cognitive, neuroimaging, and neuropathological data were collected from 69 patients with sporadic PPA, divided into 29 semantic (svPPA), 25 nonfluent (nfvPPA), 11 logopenic (lvPPA), and 4 mixed PPA. Patterns of gray matter (GM) and white matter (WM) atrophy at presentation were assessed and tested as predictors of pathological diagnosis using support vector machine (SVM) algorithms. Results: A clinical diagnosis of PPA was associated with frontotemporal lobar degeneration (FTLD) with transactive response DNA-binding protein (TDP) inclusions in 40.5%, FTLD-tau in 40.5%, and Alzheimer disease (AD) pathology in 19% of cases. Each variant was associated with 1 typical pathology; 24 of 29 (83%) svPPA showed FTLD-TDP type C, 22 of 25 (88%) nfvPPA showed FTLD-tau, and all 11 lvPPA had AD. Within FTLD-tau, 4R-tau pathology was commonly associated with nfvPPA, whereas Pick disease was observed in a minority of subjects across all variants except for lvPPA. Compared with pathologically typical cases, svPPA-tau showed significant extrapyramidal signs, greater executive impairment, and severe striatal and frontal GM and WM atrophy. nfvPPA-TDP patients lacked general motor symptoms or significant WM atrophy. Combining GM and WM volumes, SVM analysis showed 92.7% accuracy to distinguish FTLD-tau and FTLD-TDP pathologies across variants. Interpretation: Each PPA clinical variant is associated with a typical and most frequent cognitive, neuroimaging, and neuropathological profile. Specific clinical and early anatomical features may suggest rare and atypical pathological diagnosis in vivo.
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Objective: To characterize in vivo signatures of pathological diagnosis in a large cohort of patients with primary progressive aphasia (PPA) variants defined by current diagnostic classification. Methods: Extensive clinical, cognitive, neuroimaging, and neuropathological data were collected from 69 patients with sporadic PPA, divided into 29 semantic (svPPA), 25 nonfluent (nfvPPA), 11 logopenic (lvPPA), and 4 mixed PPA. Patterns of gray matter (GM) and white matter (WM) atrophy at presentation were assessed and tested as predictors of pathological diagnosis using support vector machine (SVM) algorithms. Results: A clinical diagnosis of PPA was associated with frontotemporal lobar degeneration (FTLD) with transactive response DNA-binding protein (TDP) inclusions in 40.5%, FTLD-tau in 40.5%, and Alzheimer disease (AD) pathology in 19% of cases. Each variant was associated with 1 typical pathology; 24 of 29 (83%) svPPA showed FTLD-TDP type C, 22 of 25 (88%) nfvPPA showed FTLD-tau, and all 11 lvPPA had AD. Within FTLD-tau, 4R-tau pathology was commonly associated with nfvPPA, whereas Pick disease was observed in a minority of subjects across all variants except for lvPPA. Compared with pathologically typical cases, svPPA-tau showed significant extrapyramidal signs, greater executive impairment, and severe striatal and frontal GM and WM atrophy. nfvPPA-TDP patients lacked general motor symptoms or significant WM atrophy. Combining GM and WM volumes, SVM analysis showed 92.7% accuracy to distinguish FTLD-tau and FTLD-TDP pathologies across variants. Interpretation: Each PPA clinical variant is associated with a typical and most frequent cognitive, neuroimaging, and neuropathological profile. Specific clinical and early anatomical features may suggest rare and atypical pathological diagnosis in vivo. ANN NEUROL 2017; 81:430-443 P rimary progressive aphasia (PPA) defines a group of neurodegenerative syndromes characterized by progressive, selective decline in speech and language functions. Current diagnostic classification 1 identifies 3 main clinical variants: semantic (svPPA), nonfluent/agrammatic (nfvPPA), and logopenic (lvPPA). Previous clinicopathological series [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] have shown associations between PPA variants and most probable pathological substrates. svPPA and nfvPPA are generally included in the spectrum of frontotemporal lobar degeneration (FTLD), with abnormal deposition of either transactive response DNA-binding protein of 43kD (TDP-43) or microtubule-associated protein tau, whereas lvPPA is most often associated with Alzheimer disease (AD) pathology. Nevertheless, there is no absolute association between each PPA variant and a single pathological entity. Furthermore, the relative frequency of specific molecular alterations in each variant differs greatly across studies. FTLD-tau is reported in cases classified as "nonfluent" with a frequency ranging from 50 to 100%, with most of the remainder having FTLD-TDP or, less frequently, AD pathology 2, [5] [6] [7] [8] [9] (Supplementary Table 1 ). Similarly, studies that included the most recently described logopenic variant report a frequency of AD pathology between 50 and 100% in this clinical subtype, with FTLD-TDP (often associated with GRN mutations) as the second most common cause. [3] [4] [5] [6] [12] [13] [14] By contrast, FTLD-TDP is reported in up to 90% of svPPA cases, with FTLD-tau or AD as less common pathological findings. 2, 7, [15] [16] [17] Inconsistencies across studies likely arise from use of different diagnostic approaches (many patients were diagnosed before the current classification was published), inclusion of familial cases, lack of comprehensive cognitive and neuroimaging data, and small sample sizes. The identification of in vivo features that predict a pathological diagnosis is becoming important, as pharmacological trials targeting specific molecular substrates of AD and FTLD pathologies are emerging. Cerebrospinal fluid and positron emission tomography (PET) biomarkers have proven useful in the identification of AD pathology in PPA patients, [18] [19] [20] whereas no similar tools have been validated so far for FTLD subtypes. To date, automated classification algorithms, recently used to identify neuroimaging biomarkers of several neurodegenerative diseases, [21] [22] [23] have not been applied to pathological series. This study provides a comprehensive analysis of clinical, cognitive, and neuroimaging features at clinical presentation in a large, well-characterized cohort of sporadic PPA patients with pathological diagnosis, who were evaluated at the same clinic and diagnosed using the state-of-the-art classification system. The primary aim of the study was to identify clinicopathological correlates in each PPA variant. A secondary analysis investigated whether an automated classification algorithm based on magnetic resonance imaging (MRI) variables alone could be a valid predictor of pathological diagnosis in PPA.
Patients and Methods

Subjects
Patients with a clinical diagnosis of PPA 1, 24 and postmortem neuropathological diagnosis were included. Clinical diagnosis was based on history, neurological evaluation performed at the Memory and Aging Center at University of California, San Francisco (UCSF), and review of neuroimaging findings (ie, conventional MRI, computed tomography, and/or PET scans). All included patients had at least a clinical neuroimaging evaluation, allowing for an "imaging-supported" diagnosis, based on current classification. 1 Seventy-five patients recruited between
November 1, 1998 and August 31, 2013 met these criteria. Because this study aimed to identify hallmarks of pathological features related to sporadic and otherwise unidentifiable molecular alterations, we excluded patients with a family history of dominant inherited dementia, presence of a known genetic mutation, or clinical signs/symptoms of motor neuron disease (MND) at presentation. Three patients were excluded due to the presence of autosomal dominant GRN mutation (nfvPPA clinically) or C9ORF72 expansion (svPPA clinically), and 3 because clinical signs of MND were found (Fig 1) . Therefore, the final cohort included 69 PPA patients classified as having svPPA (n 5 29), nfvPPA (n 5 25), or lvPPA (n 5 11). Four patients showed symptoms of >1 variant and were, therefore, classified as "mixed" (ie, "unclassifiable") PPA patients. Although current classification was applied retrospectively in 58 subjects presenting before 2011, these patients had been previously classified using the corresponding 2004 guidelines. 24 Note that 18 cases included here were reported in the original description of PPA clinical variants. 24 Patients were included in the neuroimaging analysis if an MRI scan was performed within 6 months from presentation and Clinical Dementia Rating (CDR) Scale score was 2. Ten subjects were excluded due to the lack of a suitable scan, whereas 1 patient had a CDR score of 3. Therefore, 58 patients were included in the neuroimaging study, namely 23 svPPA, 23 nfvPPA, 9 lvPPA, and 3 mixed PPA.
All participants signed informed consent. The study was approved by the UCSF human research committee.
Genetic Analysis
Blood samples were collected from 58 of 75 recruited patients and screened for known pathogenic mutations using optimized protocols 25 in the following genes: GRN, MAPT, TARDBP, C9ORF72, APP, PSEN1, PSEN2, FUS. APOE and MAPT H1/ H2 haplotypes were also assessed. 26 
Clinical and Cognitive Assessment
Detailed history and neurologic examination were obtained from all patients at presentation. Screening cognitive testing 27 was available from 64 patients, 53 of whom had comprehensive speech and language evaluations. 24 Five patients could not undergo formal testing due to disease severity at presentation (CDR 2), and thus, core features of PPA variants were assessed qualitatively by history and neurologic evaluation. Ten age-and gender-matched healthy controls also underwent general cognitive and language assessments (7 females, mean age 5 69.0 6 8.1 years). Demographic, clinical, and cognitive features of patients and controls were compared using Kruskal-Wallis or Pearson chi-square tests followed by pairwise post hoc analyses (Supplementary Tables 2 and 3 ). Within each clinical group, MannWhitney U or Fisher exact tests were performed to compare scores of subjects with "atypical" pathological diagnoses with those obtained from the main pathological subgroup (Tables 1  and 2 ), excluding patients with a mixed primary pathology.
Neuropathological Assessment
Autopsies were performed at UCSF (n 5 58); University of Pennsylvania (n 5 9); University of California, Davis (n 5 1); and Vancouver General Hospital (n 5 1). Pathological diagnosis was based on consensus criteria for FTLD, 28 AD, 29 and Lewy body disease (LBD). 30 Primary and secondary pathological changes were established by the pathologist in charge (W.W.S., L.T.G., E.J.H., J.Q.T.). Cases were defined as having "mixed pathology" if a single primary etiological contribution could not be established.
MRI Acquisition and Voxel-Based Morphometry Analysis
For the neuroimaging analysis, an additional set of 30 healthy controls (18 females, mean age 5 65.1 6 8.7 years) matched with patients for age, gender, and scanner type was recruited. Three-dimensional T1-weighted images with a magnetizationprepared rapid gradient echo sequence were obtained from patients and controls using either a 1.5, 31 3, 31 or 4T 32 scanner.
Voxel-based morphometry (VBM) assessed volume differences in gray matter (GM) and white matter (WM). 33 Image processing was performed in SPM12 using the DARTEL toolbox 34 running under MATLAB 2014a (MathWorks, Natick, MA). Whole-brain differences in GM and WM were investigated using analysis of variance models including age, gender, total intracranial volume, and scanner type as covariates. We compared each clinical group (ie, svPPA, nfvPPA, lvPPA, mixed PPA) and each pathological subgroup (eg, svPPA-TDP, svPPAtau, etc) with controls. Within svPPA and nfvPPA, we also tested a comparison between FTLD-tau and FTLD-TDP subjects, excluding patients with a mixed primary pathology. Threshold of significance was set at p < 0.05 corrected for familywise error (FWE). Subsequently, a more liberal threshold at p < 0.001, uncorrected, was tested to avoid false negatives that can occur in small groups.
Support Vector Machine Analysis
To test neuroimaging variables as predictors of pathological diagnosis, we entered whole-brain GM and WM probability maps in a linear support vector machine (SVM) algorithm. We adopted the LIBSVM 35 Classification accuracy of AD pathology could not be tested due to the small number of subjects (n 5 11). Feature selection was based on principal component analysis, and a 2-level crossvalidation procedure was performed. 23 
Results
Neuropathological Classification
The whole cohort of PPA patients showed FTLD-TDP in 40.5%, FTLD-tau in 40.5%, and AD pathology in 19% of cases. We identified a prevalent (ie, "typical") pathology for each variant (Fig 2) . Differences in distribution of FTLD subtypes and AD pathology were highly significant among PPA clinical variants (p < 0.001). All 29 svPPA patients showed primary FTLD pathology. FTLD-TDP type C (TDP-C) was found in 24 cases (83%), whereas 4 patients had FTLD-tau (2 Pick disease [PiD] and 2 globular glial tauopathy [GGT]). One svPPA patient had mixed FTLD-TDP type B (TDP-B) and unclassifiable FTLD-tau pathology, as it was not possible to establish a single primary pathological contribution. Of the TDP-C patients, 2 also showed secondary progressive supranuclear palsy (PSP) and 2 had secondary AD pathology.
Of 25 nfvPPA patients, 22 (88%) had a pathological diagnosis of FTLD-tau. Specifically, 18 subjects showed FTLD 4R-tau (11 corticobasal degeneration [CBD], 6 PSP, and 1 unclassifiable 4R-tauopathy), and 4 had PiD. Two subjects showed FTLD-TDP type A (TDP-A), and 1, who died at age 80 years, had mixed AD and CBD pathology. Secondary AD pathology was found in 1 nfvPPA-CBD and 1 nfvPPA-PiD case. All 11 lvPPA patients showed primary AD pathology. Of these, 2 cases showed secondary LBD, and 1 had secondary PSP pathology.
Of the 4 mixed PPA, 2 had PiD, 1 had TDP-A, and 1 had AD pathology.
Clinicopathological, Genetic, and Neuroanatomical Findings SVPPA. Demographic Data. Overall, svPPA patients showed mean age at onset of 60 years and survival of 12 years (see Table 1 ). svPPA patients with different pathological diagnoses showed no significant differences in terms of education, gender, or age (see Table 2 , Supplementary Table 2 ). Four of the 5 svPPA patients with pathology other than TDP-C lived on average 3 years less than svPPA-TDP-C. One svPPA-GGT patient showed an exceptionally long disease duration and died 19 years after onset.
Genetic Data. The ApoE4 allele was present in 29% of svPPA patients, whereas the H1/H1 MAPT haplotype was found in 54%, with no significant differences between pathological subtypes (see Table 2 , Supplementary Table 2 ). Both svPPA-TDP-C patients with secondary AD pathology had the E3/E4 genotype.
Clinical and Cognitive Data. All 29 svPPA patients presented with word-finding difficulties as the main cause of limitation in daily activities. Nineteen patients also had significant behavioral symptoms at onset (loss of empathy, irritability, obsessive/ritualistic behavior, altered eating habits), although these did not dominate the clinical presentation. Cognitive evaluation showed mild to moderate memory and executive impairment with spared visuospatial functions (see Table 1 ). The most impaired linguistic domains were naming, single-word comprehension, and semantic knowledge.
Clinical, cognitive, and linguistic features of svPPA-TDP-C patients reflected the profile of the whole svPPA group (see Supplementary Tables 2 and 3 ). Four of 5 svPPA subjects with pathology other than TDP-C showed particularly severe behavioral symptoms (ie, obsessive-compulsive behavior, disinhibition, apathy). The 2 svPPA-GGT patients also presented with severe global cognitive impairment. All svPPA-tau patients shared prominent executive impairment, performing worse than svPPA-TDP-C at digit span backward (Table  3 , p 5 0.01), modified trails (p 5 0.04), and phonemic fluency tasks (p 5 0.03). Neurologic examination was unremarkable for all svPPA-TDP-C patients, except for 1 with secondary PSP pathology showing mild vertical gaze limitation and bilateral bradykinesia. By contrast, 3 svPPA-tau and the svPPA patient with mixed TDP-B/ unclassifiable FTLD-tau showed mild to moderate extrapyramidal rigidity in the right upper limb. Unified Parkinson Disease Rating Scale motor scores were significantly higher in svPPA-tau than svPPA-TDP-C (see Table 2 , p 5 0.004).
Neuroimaging Data. Compared with healthy controls, svPPA-TDP-C patients showed GM atrophy involving the anterior temporal lobe (ATL), medial orbitofrontal cortex (OFC), and fusiform gyri bilaterally, as well as the left middle and superior temporal gyri (Fig 3A, p < 0.05  FWE) . WM atrophy involved the temporal portions of the inferior longitudinal fasciculus (ILF), inferior frontooccipital fasciculus (IFOF), and uncinate fasciculus bilaterally (p < 0.05 FWE).
The svPPA subject with mixed TDP-B/unclassifiable FTLD-tau showed GM atrophy in the left temporal pole (mostly medial) and bilateral OFC and WM atrophy in the left uncinate fasciculus (p < 0.001 uncorrected). svPPA-PiD patients showed widespread GM atrophy involving the ATL bilaterally (medial > lateral), frontal regions (ie, bilateral OFC, inferior, middle and superior frontal gyri, right anterior cingulate cortex [ACC]), insula, basal ganglia (bilateral putamen, left caudate nucleus), and left middle temporal and fusiform gyri (p < 0.001 uncorrected). Extensive WM atrophy was also found, involving the ILF, IFOF, uncinate fasciculus, forceps minor, and anterior corona radiata bilaterally (p < 0.001 uncorrected).
The svPPA-GGT subject included in the neuroimaging study (P28) showed left-lateralized GM atrophy, involving the ATL (medial > lateral), middle frontal gyrus, ACC, putamen, and caudate (p < 0.001 uncorrected). WM atrophy involved extensive temporal and frontal regions bilaterally with left prevalence (p < 0.001 uncorrected). When svPPA-TDP-C and all 3 svPPA-tau patients were compared directly, svPPA-tau patients showed more severe GM atrophy in bilateral ACC and in the left striatum (putamen, head of the caudate nucleus), as well as more prominent WM atrophy in the forceps minor, genu and body of the corpus callosum, and left anterior corona radiata (see Fig 3B, p < 0.001 uncorrected) .
NFVPPA. Demographic Data. nfvPPA patients were mostly women (18 of 25) and showed a mean age at onset of 64 years and survival of 8 years (see Table 1 ). No significant differences in gender, education, age, disease duration at presentation, and survival between pathological subgroups were found (see Table 2, Supplementary Table 2 ).
Genetic Data. ApoE4 was infrequent in nfvPPA patients (see Table 1 ) and was found only in 1 CBD case with secondary AD pathology. All tested patients with FTLD-tau showed the H1/H1 haplotype.
Clinical and Cognitive Data. All 25 nfvPPA patients presented with apraxia of speech (AOS) and/or dysarthria with mixed but prevalently hypokinetic features. Twentythree patients also had impaired grammar production or comprehension.
No patient showed isolated agrammatism, and only 2 presented with prevalent agrammatism and mild AOS. Although 20 nfvPPA patients showed neuropsychiatric symptoms, these were generally milder relative to svPPA. Extrapyramidal signs at motor examination were found in 19 nfvPPA patients. Neuropsychological testing showed executive impairment with relative sparing of memory and visuospatial abilities. Compared with nfvPPA patients with 4R-tau pathology, nfvPPA-PiD subjects did not show consistent clinical or cognitive differences (see Supplementary  Tables 2 and 3 ). However, 1 case (P50) showed a peculiar clinicoanatomical syndrome consistent with a diagnosis of crossed nfvPPA, 36 with AOS and agrammatism accompanied by clearly right more than left inferior frontal atrophy (see Neuroimaging Data) in a strongly righthanded patient with no family history of left-handedness. The 1 nfvPPA patient with mixed AD/CBD pathology also showed a typical nfvPPA syndrome but was older than other patients (74 years old). nfvPPA patients with FTLD-TDP did show some distinguishing features when compared with nfvPPA-tau. One nfvPPA-TDP-A subject (P52) showed severe, isolated motor speech deficits with spastic dysarthria, early mutism, and mild agrammatism and has been previously described in detail. 37 The second subject (P53) presented with a 5-year history of motor speech difficulties and likely severe agrammatism, although detailed description of her language profile was not feasible due to disease severity at presentation (Mini-Mental State Examination 5 8).
Despite the severity of speech and language deficits, all nfvPPA-TDP-A subjects showed spared motor functions and behavior at presentation (see Table 2 , p ranging from 0.04 to 0.05) relative to nfvPPA-tau.
Neuroimaging Data. Compared with healthy controls, nfvPPA-4R-tau patients showed GM atrophy in the left precentral gyrus, inferior frontal gyrus pars opercularis (IFG-po), supplementary motor area (SMA), superior and middle frontal gyri, insula, and putamen ( Fig 4A,  p < 0.05 FWE) . nfvPPA-4R-tau patients also showed extensive frontal WM atrophy involving the left superior longitudinal fasciculus (SLF) and the body of the corpus callosum as well as bilateral anterior corona radiata (p < 0.05 FWE). The pattern of left frontal WM atrophy traces the "frontal aslant tract." 38 In 2 of the 3 nfvPPA-PiD patients included in the neuroimaging analysis (P48, P49), GM atrophy was found in the left IFG-po, insula, middle frontal gyrus, and SMA, as well as in the precentral gyrus and OFC bilaterally. WM atrophy involved the SLF and anterior corona radiata bilaterally, with prevalence in the left hemisphere (p < 0.001 uncorrected). The case with crossed nfvPPA and PiD pathology (P50) showed selective right-sided GM atrophy involving the precentral gyrus, SMA, insula, and superior temporal pole (p < 0.001 uncorrected).
The nfvPPA patient with TDP-A pathology and neuroimaging data (P52), as previously reported, 37 showed selective GM atrophy involving the left IFG-po, precentral gyrus, insula, and inferior parietal lobule (p < 0.001 uncorrected).
The nfvPPA case with mixed AD/CBD pathology showed mild, selective GM atrophy in the left anterior IFG and inferior parietal lobule (p < 0.001 uncorrected).
When nfvPPA-tau patients were directly compared with nfvPPA-TDP, VBM analysis did not show any significant differences.
LVPPA. Demographic, clinical, cognitive, and genetic features of lvPPA patients-all diagnosed with AD pathology-are consistent with reports that first described this variant 24, 39 (see Table 1 ). ApoE4 allele incidence was high (56%), reflecting the constant presence of AD pathology in this cohort. VBM analysis showed atrophy involving mainly the GM (left middle temporal gyrus, angular gyrus, precuneus, and hippocampus) but also the left parahippocampal and anterior temporal WM (see Fig 4B, Clinical and Cognitive Data. Both mixed PPA patients with PiD presented with word-finding difficulties and impaired speech fluency. P55 showed severe AOS leading to functional mutism, whereas P56 had prominent phonological impairment. Both cases also showed severe semantic deficits, nonlinguistic cognitive impairment (memory, executive), and right-sided hemiparkinsonism. P55 also showed severe behavioral symptoms (agitation, irritability).
The mixed PPA patient with AD pathology showed moderate AOS, severe agrammatism, and impaired repetition. He also showed moderate global cognitive impairment with prominent memory deficits. Motor functions were intact.
The mixed PPA patient with TDP-A presented with severe word-finding difficulties associated with effortful speech, grammatical comprehension deficits, and impaired repetition. Nonlinguistic domains were relatively intact. Neurologic examination showed right limb apraxia but no rigidity.
Neuroimaging Data. Patients with mixed PPA and PiD showed widespread GM atrophy involving the IFG, insula, superior frontal gyrus, SMA, OFC, and precuneus bilaterally, as well as the left temporal pole, inferior temporal gyrus, and striatum (see Fig 4C, p < 0.001 uncorrected). WM atrophy was found in the left SLF, uncinate fasciculus, and anterior corona radiata (p < 0.001 uncorrected).
The mixed PPA patient with AD pathology showed selective left hippocampal and parahippocampal atrophy (p < 0.001 uncorrected). Supplementary Table 4 displays the statistical measures (ie, sensitivity, specificity, accuracy, area under the receiver operating characteristic curve [AUC] ) that describe SVM classification of healthy controls and PPA patients with FTLD-tau and FTLD-TDP based on VBM probability maps. A combination of GM and WM measures showed the best performance (accuracy 5 92.7%, AUC 5 96.4%) in distinguishing PPA patients with FTLD-tau from those with FTLD-TDP regardless of their clinical diagnoses. Figure 5 shows SVM classification at a single-patient level. It is noteworthy that when WM measures were included, all 4 patients with "atypical" pathology were classified correctly.
SVM MRI Analysis
Discussion
This study provides a comprehensive analysis of clinical, cognitive, and neuroimaging features of the largest reported cohort of sporadic PPA patients with pathological confirmation, diagnosed using modern clinical classification. Our aim was to determine in vivo signatures of neuropathological alterations within the spectrum of PPA clinical variants in the absence of known genetic mutations. Each clinical variant was associated with a highly typical (83-100%) pathological correlate, demonstrating the utility of the modern classification system for prediction of pathological findings. Specific clinical and neuroimaging features suggested the presence of "atypical" pathology. Automated machine learning analyses highlighted the power of MRI variables in predicting pathology.
The most typical pathology of svPPA was TDP-C (found in 83% of cases), whereas nfvPPA was typically associated with FTLD-tau (88%). "Atypical" neuropathological diagnoses in svPPA included TDP-B and tauopathies such as PiD and GGT, whereas alternative pathological substrates of nfvPPA included TDP-A and AD (in 1 case with coprimary 4R-tau). In our cohort, no case of svPPA or nfvPPA had pure AD pathology, although AD changes co-occurred with FTLD in 3 cases. These findings highlight how, in the presence of specific clinical and neuroimaging features, a diagnosis of svPPA and nfvPPA consistently predicts underlying FTLD pathology. Instead, all lvPPA patients showed primary AD pathology, in keeping with a selective vulnerability of posterior brain networks to AD. 18, 19, 40 Interestingly, clinicopathological correspondence was complete, indicating lvPPA clinical and neuroimaging syndrome as an important in vivo predictor of AD pathology in sporadic PPA. However, neuronal vulnerability to molecular changes is not absolute, and our lvPPA cohort was relatively small. Therefore, some FTLD cases are likely to emerge in larger cohorts. 41 Our finding is in contrast with previous studies showing TDP-A pathology in 15 to 25% of lvPPA cases. 2, 4, 6 Finally, 3 of 4 patients with a mixed PPA phenotype showed FTLD pathology and were most probably later, more severe presentations of 1 of the 3 main variants. Overall, our findings demonstrate that the current clinical classification system of PPA variants allows for strong, but not absolute, clinicopathological predictions in each of the 3 main subtypes. Furthermore, detailed analysis of the case series with "atypical" pathological diagnoses suggests that early clinical and anatomical features might predict less frequent molecular correlates. Typical FTLD-TDP pathology in svPPA was associated with the characteristic semantic memory impairment and selective ATL atrophy, accompanied by mild to moderate neuropsychiatric abnormalities in 40% of patients. The "atypical" svPPA-tau cases showed greater executive and motor involvement and a trend toward more severe behavioral symptoms (apathy and/or disinhibition), likely in relation to greater atrophy of frontotemporal cortex (ie, medial ATL, OFC, ACC), basal ganglia, and connecting WM structures. 15, 42 Although disease duration might be a factor in determining these differences, atypical symptoms were also present in svPPA-tau cases with comparable age and disease duration relative to svPPA-TDP. Interestingly, frontal WM damage was particularly widespread in svPPA-tau, whereas WM atrophy in the svPPA-TDP group was confined to the ATL. This finding is consistent with previous imaging studies showing greater WM diffusion changes in FTLD-tau relative to FTLD-TDP regardless of clinical presentation. 43, 44 Furthermore, evidence that WM is more susceptible to early damage in FTLD-tau comes from cellular and animal models suggesting that tau aggregates primarily impair axonal transport. 45, 46 By contrast, although trans-synaptic spreading of TDP-43 depositions has been reported, 47 FTLD-TDP primarily affects the GM, involving the WM at later stages of disease. 48 Taken together, our results suggest that the focal cognitive and neuroanatomical syndrome of svPPA is highly predictive of FTLD-TDP pathology, particularly TDP-C, whereas an early clinical and anatomical involvement of frontostriatal structures might suggest FTLD-tau. In our study, an imaging-supported diagnosis of nfvPPA was associated with FTLD-tau pathology in nearly 90% of cases, with 4R-tau being the most common subtype. Sporadic TDP-A was rare (8%), and AD was never present in isolation. The lack of pure AD pathology in our nfvPPA cohort is likely related to the reliable differential diagnosis with lvPPA, as will be discussed in the next paragraph. The strong association of nfvPPA clinical and neuroanatomical syndrome with FTLD-tau pathology is consistent but even stronger than in other previous studies in which FTLD-TDP was more frequently reported. 2, 4, 5, 8 Even the inclusion of 2 cases with GRN mutations, which were excluded from our analysis, would have increased TDP-A frequency to only 14%. The consistent association between nfvPPA and FTLDtau has important clinical implications, indicating that these patients should be included in tau-targeting pharmacological trials. Comparing features of nfvPPA-4R-tau patients with those with nfvPPA-TDP, current results also confirm our previous findings, 37 showing greater motor speech abnormalities than agrammatism in all but 2 patients and earlier general motor abnormalities and greater WM changes in nfvPPA-tau cases. These findings are consistent with the biological features of FTLD-tau and FTLD-TDP mentioned previously. We also describe 4 nfvPPA patients with PiD (a 3R-tauopathy). They did not show distinguishing clinical or cognitive traits relative to 4R-tau patients, although we did observe some additional right frontoinsular atrophy (possibly explained by the more liberal threshold adopted for small-group VBM analyses). One right-handed nfvPPA-PiD case presented with selective right-sided atrophy, similarly to a recent case report of "crossed" nfvPPA. 36 Of note, PiD occurred across all variants except for lvPPA. This supports the hypothesis that PiD presents with a variable frontotemporal pattern of atrophy, leading to different clinical correlates within the spectrum of frontotemporal degeneration disorders. 7 The extensive involvement of multiple functional networks might also explain the early global impairment observed in some patients with PiD here reported. 49 In our cohort, lvPPA was the variant showing the most consistent clinicopathological association, namely with AD pathology. In early reports, lvPPA might have been included in the "nonfluent" category, explaining the high prevalence of AD reported by some of these studies in nonfluent cases. 10, 11 More recently, TDP-A was also found in a few lvPPA cases 2,4,6 who might have been GRN mutation carriers and thus excluded here. In our study, conventional neuroimaging was also reviewed at the time of clinical diagnosis, allowing for an "imagingsupported" diagnosis, which is likely to be more consistent with pathology. That our cohort of pathologically proven lvPPA is smaller than the other 2 main groups may be partially explained by the longer survival we found in lvPPA patients, in keeping with studies showing a more aggressive clinical course of FTLD-related disorders compared with AD. 50 Although we do not expect that larger cohorts will show a 100% association between lvPPA and AD pathology, large biomarker studies do indicate that AD is the most typical pathology in lvPPA. [18] [19] [20] In summary, our findings, together with previous evidence, suggest that the clinical and neuroimaging diagnostic features of lvPPA are highly predictive of underlying AD. A secondary aim of the present study was to quantify the extent to which neuroimaging may help in classifying individual PPA patients according to the specific FTLD subtype. Machine learning has been recently applied to identify early MRI-based diagnostic markers of neurodegenerative diseases, 21, 22 including PPA variants. 23 However, this is the first study testing this approach for the pathological diagnosis of PPA syndromes. SVM analysis of differential patterns of GM and WM damage across variants did prove useful in the identification of FTLD-tau and FTLD-TDP in this cohort, because a combination of both parameters showed the best accuracy (92.7%) classifying FTLD subtypes. Compared with the approximate 85% probability of patients diagnosed with svPPA and nfvPPA to have, respectively, underlying FTLD-TDP or FTLD-tau, this approach was shown to be partially helpful in atypical cases. Particularly, the pattern of WM atrophy provided higher accuracy than GM alone in the correct classification of svPPA-tau and nfvPPA-TDP patients. These results strengthen the hypothesis that the differential involvement of WM shown by neuroimaging may constitute a key biomarker to discriminate FTLD subtypes. This study has some limitations. Despite the robust size of the overall cohort, some subgroups were small, reflecting the rarity of atypical pathological diagnoses within an uncommon disease. Therefore, the degree to which the clinical and neuroimaging features of these cases can be generalized to other populations is unclear. For the same reason, the SVM analysis had to be crossvalidated within the cohort itself-a commonly adopted approach when limited samples are available 22,23 -and could not be applied reliably to patients with AD pathology. Finally, diffusion tensor imaging data were unavailable for most included subjects. Nevertheless, VBM proved sufficiently sensitive to WM damage, even in small groups.
In conclusion, our findings suggest that current clinical classification criteria can be used to predict a most probable pathological diagnosis within each PPA clinical variant. Early, unusual clinical, cognitive, and neuroanatomical distinctive traits may suggest atypical pathological correlates. We also shown that automated methods processing multimodal neuroimaging features may assist in the discrimination of FTLD subtypes in PPA. As therapies targeting specific disease mechanisms emerge, clinical and neuroimaging techniques detecting early pathological alterations may constitute a crucial diagnostic tool.
